Literature DB >> 34365229

Post-translational modification of RAS proteins.

Sharon L Campbell1, Mark R Philips2.   

Abstract

Mutations of RAS genes drive cancer more frequently than any other oncogene. RAS proteins integrate signals from a wide array of receptors and initiate downstream signaling through pathways that control cellular growth. RAS proteins are fundamentally binary molecular switches in which the off/on state is determined by the binding of GDP or GTP, respectively. As such, the intrinsic and regulated nucleotide-binding and hydrolytic properties of the RAS GTPase were historically believed to account for the entirety of the regulation of RAS signaling. However, it is increasingly clear that RAS proteins are also regulated by a vast array of post-translational modifications (PTMs). The current challenge is to understand what are the functional consequences of these modifications and which are physiologically relevant. Because PTMs are catalyzed by enzymes that may offer targets for drug discovery, the study of RAS PTMs has been a high priority for RAS biologists.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; GTPase; Post-translational modification; RAS; Signaling

Mesh:

Substances:

Year:  2021        PMID: 34365229      PMCID: PMC8649064          DOI: 10.1016/j.sbi.2021.06.015

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN: 0959-440X            Impact factor:   6.809


  137 in total

1.  Regulation of RAS oncogenicity by acetylation.

Authors:  Moon Hee Yang; Seth Nickerson; Eric T Kim; Caroline Liot; Gaelle Laurent; Robert Spang; Mark R Philips; Yibing Shan; David E Shaw; Dafna Bar-Sagi; Marcia C Haigis; Kevin M Haigis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Lipid-binding characteristics of the polybasic carboxy-terminal sequence of K-ras4B.

Authors:  R Leventis; J R Silvius
Journal:  Biochemistry       Date:  1998-05-19       Impact factor: 3.162

Review 3.  ROS in Cancer: The Burning Question.

Authors:  Iok In Christine Chio; David A Tuveson
Journal:  Trends Mol Med       Date:  2017-04-17       Impact factor: 11.951

4.  Rabex-5 ubiquitin ligase activity restricts Ras signaling to establish pathway homeostasis in Drosophila.

Authors:  Hua Yan; Maryam Jahanshahi; Elizabeth A Horvath; Hsiu-Yu Liu; Cathie M Pfleger
Journal:  Curr Biol       Date:  2010-07-22       Impact factor: 10.834

5.  Nitric oxide-stimulated guanine nucleotide exchange on p21ras.

Authors:  H M Lander; J S Ogiste; S F Pearce; R Levi; A Novogrodsky
Journal:  J Biol Chem       Date:  1995-03-31       Impact factor: 5.157

6.  The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer.

Authors:  Zurab Siprashvili; Dan E Webster; Danielle Johnston; Rajani M Shenoy; Alexander J Ungewickell; Aparna Bhaduri; Ross Flockhart; Brian J Zarnegar; Yonglu Che; Francesca Meschi; Joseph D Puglisi; Paul A Khavari
Journal:  Nat Genet       Date:  2015-11-23       Impact factor: 38.330

Review 7.  Mevalonate pathway: a review of clinical and therapeutical implications.

Authors:  Irina Buhaescu; Hassane Izzedine
Journal:  Clin Biochem       Date:  2007-03-31       Impact factor: 3.281

8.  ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth.

Authors:  Jarrett R Remsberg; Radu M Suciu; Noemi A Zambetti; Thomas W Hanigan; Ari J Firestone; Anagha Inguva; Amanda Long; Nhi Ngo; Kenneth M Lum; Cassandra L Henry; Stewart K Richardson; Marina Predovic; Ben Huang; Melissa M Dix; Amy R Howell; Micah J Niphakis; Kevin Shannon; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2021-04-29       Impact factor: 16.174

Review 9.  Protein prenylation: enzymes, therapeutics, and biotechnology applications.

Authors:  Charuta C Palsuledesai; Mark D Distefano
Journal:  ACS Chem Biol       Date:  2014-12-08       Impact factor: 5.100

10.  Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers.

Authors:  Shaun S Sanders; Dale D O Martin; Stefanie L Butland; Mathieu Lavallée-Adam; Diego Calzolari; Chris Kay; John R Yates; Michael R Hayden
Journal:  PLoS Comput Biol       Date:  2015-08-14       Impact factor: 4.475

View more
  7 in total

Review 1.  Pathological implication of protein post-translational modifications in cancer.

Authors:  Sheng Pan; Ru Chen
Journal:  Mol Aspects Med       Date:  2022-04-07

Review 2.  Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation.

Authors:  E Sila Ozdemir; Anna M Koester; Xiaolin Nan
Journal:  Genes (Basel)       Date:  2022-01-25       Impact factor: 4.096

3.  A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation.

Authors:  Dhirendra K Simanshu; Deborah K Morrison
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 39.397

Review 4.  Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer.

Authors:  Jennifer J Lee; Vaibhav Jain; Ravi K Amaravadi
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

Review 5.  Noncoding RNAs in the Glycolysis of Ovarian Cancer.

Authors:  Chunmei Zhang; Ning Liu
Journal:  Front Pharmacol       Date:  2022-03-30       Impact factor: 5.810

Review 6.  Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids.

Authors:  Manuel Torres; Sebastià Parets; Javier Fernández-Díaz; Roberto Beteta-Göbel; Raquel Rodríguez-Lorca; Ramón Román; Victoria Lladó; Catalina A Rosselló; Paula Fernández-García; Pablo V Escribá
Journal:  Membranes (Basel)       Date:  2021-11-24

7.  A saturation-mutagenesis analysis of the interplay between stability and activation in Ras.

Authors:  Frank Hidalgo; Laura M Nocka; Neel H Shah; Kent Gorday; Naomi R Latorraca; Pradeep Bandaru; Sage Templeton; David Lee; Deepti Karandur; Jeffrey G Pelton; Susan Marqusee; David Wemmer; John Kuriyan
Journal:  Elife       Date:  2022-03-11       Impact factor: 8.713

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.